annual CFO:
-$237.47M+$42.55M(+15.19%)Summary
- As of today (July 1, 2025), TVTX annual cash flow from operations is -$237.47 million, with the most recent change of +$42.55 million (+15.19%) on December 31, 2024.
- During the last 3 years, TVTX annual CFO has fallen by -$222.68 million (-1505.43%).
- TVTX annual CFO is now -3307.82% below its all-time high of $7.40 million, reached on December 31, 2017.
Performance
TVTX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$42.19M-$6.47M(-18.12%)Summary
- As of today (July 1, 2025), TVTX quarterly cash flow from operations is -$42.19 million, with the most recent change of -$6.47 million (-18.12%) on March 31, 2025.
- Over the past year, TVTX quarterly CFO has increased by +$76.81 million (+64.54%).
- TVTX quarterly CFO is now -231.60% below its all-time high of $32.06 million, reached on September 30, 2021.
Performance
TVTX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$160.66M+$76.81M(+32.34%)Summary
- As of today (July 1, 2025), TVTX TTM cash flow from operations is -$160.66 million, with the most recent change of +$76.81 million (+32.34%) on March 31, 2025.
- Over the past year, TVTX TTM CFO has increased by +$157.25 million (+49.46%).
- TVTX TTM CFO is now -2270.26% below its all-time high of $7.40 million, reached on December 31, 2017.
Performance
TVTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TVTX Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +15.2% | +64.5% | +49.5% |
| 3 y3 years | -1505.4% | +23.7% | -268.2% |
| 5 y5 years | -307.9% | -44.7% | -196.3% |
TVTX Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -1505.4% | +15.2% | -18.1% | +64.5% | -84.8% | +49.5% |
| 5 y | 5-year | -1505.4% | +15.2% | -231.6% | +64.5% | -8900.8% | +49.5% |
| alltime | all time | -3307.8% | +15.2% | -231.6% | +64.5% | -2270.3% | +49.5% |
TVTX Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$42.19M(+18.1%) | -$160.66M(-32.3%) |
| Dec 2024 | -$237.47M(-15.2%) | -$35.72M(-16.0%) | -$237.47M(-12.8%) |
| Sep 2024 | - | -$42.51M(+5.6%) | -$272.23M(-5.8%) |
| Jun 2024 | - | -$40.24M(-66.2%) | -$288.86M(-9.1%) |
| Mar 2024 | - | -$119.00M(+68.9%) | -$317.91M(+13.5%) |
| Dec 2023 | -$280.02M(+50.3%) | -$70.47M(+19.2%) | -$280.02M(+6.0%) |
| Sep 2023 | - | -$59.13M(-14.7%) | -$264.19M(+8.0%) |
| Jun 2023 | - | -$69.30M(-14.6%) | -$244.58M(+15.3%) |
| Mar 2023 | - | -$81.12M(+48.5%) | -$212.09M(+13.8%) |
| Dec 2022 | -$186.29M(+1159.4%) | -$54.64M(+38.2%) | -$186.29M(+17.5%) |
| Sep 2022 | - | -$39.52M(+7.4%) | -$158.53M(+82.3%) |
| Jun 2022 | - | -$36.81M(-33.5%) | -$86.94M(+99.2%) |
| Mar 2022 | - | -$55.32M(+105.8%) | -$43.64M(+195.0%) |
| Dec 2021 | -$14.79M(-65.4%) | -$26.88M(-183.8%) | -$14.79M(+728.7%) |
| Sep 2021 | - | $32.06M(+393.6%) | -$1.78M(-93.4%) |
| Jun 2021 | - | $6.50M(-124.5%) | -$27.11M(-32.3%) |
| Mar 2021 | - | -$26.47M(+90.9%) | -$40.06M(-6.3%) |
| Dec 2020 | -$42.74M(-26.6%) | -$13.87M(-305.9%) | -$42.74M(+28.1%) |
| Sep 2020 | - | $6.74M(-204.4%) | -$33.37M(-38.5%) |
| Jun 2020 | - | -$6.45M(-77.9%) | -$54.22M(-18.9%) |
| Mar 2020 | - | -$29.16M(+549.0%) | -$66.88M(+14.9%) |
| Dec 2019 | -$58.21M(+133.2%) | -$4.49M(-68.2%) | -$58.21M(+1.6%) |
| Sep 2019 | - | -$14.12M(-26.1%) | -$57.29M(+21.7%) |
| Jun 2019 | - | -$19.11M(-6.7%) | -$47.06M(+53.2%) |
| Mar 2019 | - | -$20.49M(+474.8%) | -$30.72M(+23.1%) |
| Dec 2018 | -$24.96M(-437.1%) | -$3.56M(-8.6%) | -$24.96M(+12.2%) |
| Sep 2018 | - | -$3.90M(+41.3%) | -$22.25M(+83.1%) |
| Jun 2018 | - | -$2.76M(-81.3%) | -$12.15M(+209.6%) |
| Mar 2018 | - | -$14.73M(+1625.3%) | -$3.92M(-153.0%) |
| Dec 2017 | $7.40M | -$854.00K(-113.8%) | $7.40M(-3236.9%) |
| Sep 2017 | - | $6.20M(+13.4%) | -$236.00K(-86.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | $5.47M(-260.4%) | -$1.80M(-45.0%) |
| Mar 2017 | - | -$3.41M(-59.9%) | -$3.28M(-4.6%) |
| Dec 2016 | -$3.44M(+147.7%) | -$8.49M(-283.5%) | -$3.44M(-329.4%) |
| Sep 2016 | - | $4.63M(+16.0%) | $1.50M(-162.8%) |
| Jun 2016 | - | $3.99M(-211.9%) | -$2.39M(-245.9%) |
| Mar 2016 | - | -$3.57M(+0.4%) | $1.64M(-217.9%) |
| Dec 2015 | -$1.39M(-97.0%) | -$3.55M(-580.6%) | -$1.39M(-80.0%) |
| Sep 2015 | - | $739.00K(-90.8%) | -$6.93M(-70.1%) |
| Jun 2015 | - | $8.02M(-221.6%) | -$23.17M(-45.7%) |
| Mar 2015 | - | -$6.59M(-27.5%) | -$42.64M(-7.0%) |
| Dec 2014 | -$45.85M(+160.7%) | -$9.10M(-41.3%) | -$45.85M(+2.1%) |
| Sep 2014 | - | -$15.50M(+35.4%) | -$44.90M(+40.1%) |
| Jun 2014 | - | -$11.45M(+16.8%) | -$32.06M(+40.5%) |
| Mar 2014 | - | -$9.81M(+20.4%) | -$22.82M(+29.7%) |
| Dec 2013 | -$17.59M(+542.7%) | -$8.15M(+206.8%) | -$17.59M(+86.3%) |
| Sep 2013 | - | -$2.66M(+20.2%) | -$9.44M(+39.1%) |
| Jun 2013 | - | -$2.21M(-51.8%) | -$6.79M(+48.2%) |
| Mar 2013 | - | -$4.58M(<-9900.0%) | -$4.58M(<-9900.0%) |
| Dec 2012 | -$2.74M(<-9900.0%) | - | - |
| Nov 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2012 | - | $0.00(0.0%) | $0.00(0.0%) |
| Feb 2012 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Feb 2012 | $0.00(-100.0%) | - | - |
| Nov 2011 | - | $0.00(0.0%) | -$600.00(-14.3%) |
| Aug 2011 | - | $0.00(0.0%) | -$700.00(0.0%) |
| May 2011 | - | $0.00(-100.0%) | -$700.00(0.0%) |
| Feb 2011 | -$700.00 | -$600.00(+500.0%) | -$700.00(+600.0%) |
| Nov 2010 | - | -$100.00(<-9900.0%) | -$100.00(<-9900.0%) |
| Aug 2010 | - | $0.00(0.0%) | $0.00(0.0%) |
| May 2010 | - | $0.00 | $0.00 |
FAQ
- What is Travere Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Travere Therapeutics?
- What is Travere Therapeutics annual CFO year-on-year change?
- What is Travere Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Travere Therapeutics?
- What is Travere Therapeutics quarterly CFO year-on-year change?
- What is Travere Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Travere Therapeutics?
- What is Travere Therapeutics TTM CFO year-on-year change?
What is Travere Therapeutics annual cash flow from operations?
The current annual CFO of TVTX is -$237.47M
What is the all time high annual CFO for Travere Therapeutics?
Travere Therapeutics all-time high annual cash flow from operations is $7.40M
What is Travere Therapeutics annual CFO year-on-year change?
Over the past year, TVTX annual cash flow from operations has changed by +$42.55M (+15.19%)
What is Travere Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TVTX is -$42.19M
What is the all time high quarterly CFO for Travere Therapeutics?
Travere Therapeutics all-time high quarterly cash flow from operations is $32.06M
What is Travere Therapeutics quarterly CFO year-on-year change?
Over the past year, TVTX quarterly cash flow from operations has changed by +$76.81M (+64.54%)
What is Travere Therapeutics TTM cash flow from operations?
The current TTM CFO of TVTX is -$160.66M
What is the all time high TTM CFO for Travere Therapeutics?
Travere Therapeutics all-time high TTM cash flow from operations is $7.40M
What is Travere Therapeutics TTM CFO year-on-year change?
Over the past year, TVTX TTM cash flow from operations has changed by +$157.25M (+49.46%)